Advertisement

Onychomycosis: Topical Therapy and Devices

  • Shari R. Lipner
  • Richard K. Scher
Chapter

Abstract

Onychomycosis is a common condition and accounts for 50% of all nail diseases. Dermatophyte organisms are responsible for most cases of toenail onychomycosis, with Trichophyton rubrum and Trichophyton mentagrophytes, representing the first and second most commonly isolated organisms in the United States (US). Nondermatophyte molds, such as Fusarium and Acremonium and yeasts such as Candida parapsilosis are responsible for the remaining cases. This chapter will review treatment options for onychomycosis for adults and children, including nail avulsion, available topical therapies, as well as those in clinical trials. Lasers, photodynamic therapy, devices, such as non-thermal plasma, and over the counter treatments will also be discussed.

Keywords

Onychomycosis Topical therapy Devices Lasers 

Supplementary material

324020_4_En_11_MOESM1_ESM.pdf (29 kb)
Patient Handout (PDF 28 kb)

References

  1. 1.
    Scher RK, Rich P, Pariser D, Elewski B. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013;32(2 Suppl 1):S2–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R, Taskforce on Onychomycosis E. Treatment options – development of consensus guidelines. J Eur Acad Dermatol Venereol JEADV. 2005;19(Suppl 1):25–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Scher RK, Tosti A, Joseph WS, Vlahovic TC, Plasencia J, Markinson BC, et al. Onychomycosis diagnosis and management: perspectives from a joint dermatology-podiatry roundtable. J Drugs Dermatol JDD. 2015;14(9):1016–21.PubMedGoogle Scholar
  4. 4.
    Feldstein S, Totri C, Friedlander SF. Antifungal therapy for onychomycosis in children. Clin Dermatol. 2015;33(3):333–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014;7(7):10–8.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Stokes JH. Letter to referring physician – 1938. Int J Dermatol. 1999;38(11):827. 9, 40.PubMedGoogle Scholar
  7. 7.
    Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013;31(5):544–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Pandhi D, Verma P. Nail avulsion: indications and methods (surgical nail avulsion). Indian J Dermatol Venereol Leprol. 2012;78(3):299–308.CrossRefPubMedGoogle Scholar
  9. 9.
    Lai WY, Tang WY, Loo SK, Chan Y. Clinical characteristics and treatment outcomes of patients undergoing nail avulsion surgery for dystrophic nails. Hong Kong Med J (Xianggang yi xue za zhi/Hong Kong Acad Med). 2011;17(2):127–31.Google Scholar
  10. 10.
    Elewski B, Pariser D, Rich P, Scher RK. Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg. 2013;32(2 Suppl 1):S9–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149(Suppl 65):5–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Flagothier C, Pierard-Franchimont C, Pierard GE. New insights into the effect of amorolfine nail lacquer. Mycoses. 2005;48(2):91–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Gupta AK, Simpson FC. Routes of drug delivery into the nail apparatus: implications for the efficacy of topical nail solutions in onychomycosis. J Dermatolog Treat. 2015:1–3.Google Scholar
  14. 14.
    Polak A. Preclinical data and mode of action of amorolfine. Dermatology. 1992;184(Suppl 1):3–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Insert AP. Amorolfine 5% W/V Nail Lacquer: Medicines and Healthcare Products Regulatory Agency; 2011. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con129125.pdf2011.
  16. 16.
    Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M, Faergemann J, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007;157(1):149–57.CrossRefPubMedGoogle Scholar
  17. 17.
    Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28(12):1989–95.CrossRefPubMedGoogle Scholar
  18. 18.
    Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000;43(4 Suppl):S57–69.CrossRefPubMedGoogle Scholar
  19. 19.
    Penlac. Package insert: Penlac nail lacquer (Ciclopirox) topical solution, 8%: Dermik Laboratories; 2004 [21 June 2014]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf2004.
  20. 20.
    Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Jublia. Package insert: Jublia (efinaconazole 10% solution) [June 26 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf.
  22. 22.
    Rock FL, Mao W, Yaremchuk A, Tukalo M, Crepin T, Zhou H, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007;316(5832):1759–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Elewski BE, Aly R, Baldwin SL, Gonzalez Soto RF, Rich P, Weisfeld M, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Kerydin. Package insert: Kerydin (tavaborole) topical solution, 5% [June 26 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl.pdf.
  25. 25.
    Elewski BE, Ghannoum MA, Mayser P, Gupta AK, Korting HC, Shouey RJ, et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol JEADV. 2013;27(3):287–94.CrossRefPubMedGoogle Scholar
  26. 26.
    Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. 2014;57:389–93.CrossRefPubMedGoogle Scholar
  27. 27.
    Wiederhold NP, Fothergill AW, McCarthy DI, Tavakkol A. Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis. Antimicrob Agents Chemother. 2014;58(6):3553–5.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Trial C. Safety and efficacy of luliconazole solution, 10% in subjects with mild to moderate onychomycosis (SOLUTION): Topica Pharmaceuticals; 2013 [21 June 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT01431820.
  29. 29.
    Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, Shear NH, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol. 1997;36(3 Pt 1):395–402.CrossRefPubMedGoogle Scholar
  30. 30.
    Leibovici V, Evron R, Dunchin M, Westerman M, Ingber A. A population-based study of toenail onychomycosis in Israeli children. Pediatr Dermatol. 2009;26(1):95–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Singal A, Khanna D. Onychomycosis: diagnosis and management. Indian J Dermatol Venereol Leprol. 2011;77(6):659–72.CrossRefPubMedGoogle Scholar
  32. 32.
    Friedlander SF, Chan YC, Chan YH, Eichenfield LF. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol. 2013;30(3):316–22.CrossRefPubMedGoogle Scholar
  33. 33.
    Pena-Penabad C, Garcia-Silva J, Almagro M, del Pozo J, Fonseca E. Superficial white onychomycosis in a 3-year-old human immunodeficiency virus-infected child. J Eur Acad Dermatol Venereol JEADV. 2001;15(1):51–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Hsu MM. Rapid response of distal subungual onychomycosis to 5% amorolfine nail lacquer in a 20-month-old healthy infant. Pediatr Dermatol. 2006;23(4):410–1.CrossRefPubMedGoogle Scholar
  35. 35.
    Liddell LT, Rosen T. Laser therapy for onychomycosis: fact or fiction? J Fungi. 2015;1(1):44–54.CrossRefGoogle Scholar
  36. 36.
    Choi MJ, Zheng Z, Goo B, Cho SB. Antifungal effects of a 1444-nm neodymium:yttrium-aluminum-garnet laser on onychomycosis: a pilot study. J Dermatolog Treat. 2014;25(4):294–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol. 2013;69(4):578–82.CrossRefPubMedGoogle Scholar
  38. 38.
    Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther. 2011;13(1):2–5.CrossRefPubMedGoogle Scholar
  39. 39.
    Kimura U, Takeuchi K, Kinoshita A, Takamori K, Hiruma M, Suga Y. Treating onychomycoses of the toenail: clinical efficacy of the sub-millisecond 1,064 nm Nd: YAG laser using a 5 mm spot diameter. J Drugs Dermatol: JDD. 2012;11(4):496–504.PubMedGoogle Scholar
  40. 40.
    Waibel J, Wulkan AJ, Rudnick A. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J Drugs Dermatol: JDD. 2013;12(11):1237–42.PubMedGoogle Scholar
  41. 41.
    Hollmig ST, Rahman Z, Henderson MT, Rotatori RM, Gladstone H, Tang JY. Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol. 2014;70(5):911–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Zhang RN, Wang DK, Zhuo FL, Duan XH, Zhang XY, Zhao JY. Long-pulse Nd:YAG 1064-nm laser treatment for onychomycosis. Chin Med J. 2012;125(18):3288–91.PubMedGoogle Scholar
  43. 43.
    Moon SH, Hur H, Oh YJ, Choi KH, Kim JE, Ko JY, et al. Treatment of onychomycosis with a 1,064-nm long-pulsed Nd:YAG laser. J Cosmet Laser Ther. 2014;16(4):165–70.CrossRefPubMedGoogle Scholar
  44. 44.
    Noguchi H, Miyata K, Sugita T, Hiruma M, Hiruma M. Treatment of onychomycosis using a 1064nm Nd:YAG laser. Med Mycol J. 2013;54(4):333–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Hees H, Jager MW, Raulin C. Treatment of onychomycosis using the 1 064 nm Nd:YAG laser: a clinical pilot study. J Ger Soc Dermatol JDDG (Journal der Deutschen Dermatologischen Gesellschaft). 2014;12(4):322–9.Google Scholar
  46. 46.
    Kalokasidis K, Onder M, Trakatelli MG, Richert B, Fritz K. The effect of Q-switched Nd:YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo. Dermatol Res Pract. 2013;2013:379725.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Landsman AS, Robbins AH, Angelini PF, Wu CC, Cook J, Oster M, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc. 2010;100(3):166–77.CrossRefPubMedGoogle Scholar
  48. 48.
    Lim EH, Kim HR, Park YO, Lee Y, Seo YJ, Kim CD, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol. 2014;70(5):918–23.CrossRefPubMedGoogle Scholar
  49. 49.
    Heinemann IU, Jahn M, Jahn D. The biochemistry of heme biosynthesis. Arch Biochem Biophys. 2008;474(2):238–51.CrossRefPubMedGoogle Scholar
  50. 50.
    Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, Apalla Z, Ioannides D. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol. 2010;90(2):216–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Heinlin J, Maisch T, Zimmermann JL, Shimizu T, Holzmann T, Simon M, et al. Contact-free inactivation of Trichophyton rubrum and Microsporum canis by cold atmospheric plasma treatment. Future Microbiol. 2013;8(9):1097–106.CrossRefPubMedGoogle Scholar
  52. 52.
    Zemel M, Friedman G, Park S. Personal communication, in vitro nail studies with plasma. 2014.Google Scholar
  53. 53.
    Ouf SA, El-Adly AA, Mohamed AH. Inhibitory effect of silver nanoparticles mediated by atmospheric pressure air cold plasma jet against dermatophyte fungi. J Med Microbiol. 2015;64:1151–61.CrossRefPubMedGoogle Scholar
  54. 54.
    Lipner SR, Friedman G, Scher RK. Pilot study to evaluate a plasma device in the treatment of onychomycosis, submitted. 2015.Google Scholar
  55. 55.
    Halteh P, Lipner SR, Scher RK. Over the counter and natural remedies for onychomycosis: do they really work? Cutis, Accepted. 2015.Google Scholar
  56. 56.
    Jo Siu WJ, Tatsumi Y, Senda H, Pillai R, Nakamura T, Sone D, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57(4):1610–6.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006;49(15):4447–50.CrossRefPubMedGoogle Scholar
  58. 58.
    Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42(2 Pt 1):217–24.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Weill Cornell MedicineNew YorkUSA

Personalised recommendations